FDA has recently revised Form 356h: Application to Market a New or Abbreviated New Drug or Biologic for Human Use and Form 1571: Investigational New Drug Application (IND) to align with FDA User Fee requirements as well as make other improvements to data quality and ease of use.
These forms are required to be submitted with NDAs, ANDAs, BLAs and INDs. FDA uses this information in the review process and companies should be aware of these updates and are required to use the most current version of these forms.
Companies need to use the most recent update to Forms 356h and 1571 in their submissions.
View referenced article
Author(s)
Related Insights
June 13, 2025
Foley Viewpoints
Eighth Circuit Affirms Summary Judgment to Insurer in Dispute with Construction Project Owner Over Lost Rental Income
On Monday, June 9, 2025, the Eighth Circuit Court of Appeals ruled that a Missouri real estate developer could not recover insurance…
June 13, 2025
Foley Viewpoints
Your Company Received an ICE Notice of Inspection — Now What?
“Worksite enforcement operations are going to massively expand,” according to a June 12, 2025, interview[1] with Border Czar Tom Homan….
June 12, 2025
Legal News: International Trade Enforcement & Compliance
Tips for Avoiding Investigations of Business Fraud in India
Fraud continues to pose significant challenges across industries worldwide. For multinational companies operating in India, the country offers enormous opportunity — but also presents distinct operational and regulatory risks that require executive-level attention and strategic oversight.